CS-8958 + CS-8958 + oseltamivir phosphate

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Influenza, Human

Conditions

Influenza, Human

Trial Timeline

Nov 1, 2008 → Jun 1, 2009

NCT ID

NCT00803595

About CS-8958 + CS-8958 + oseltamivir phosphate

CS-8958 + CS-8958 + oseltamivir phosphate is a phase 3 stage product being developed by Daiichi Sankyo for Influenza, Human. The current trial status is completed. This product is registered under clinical trial identifier NCT00803595. Target conditions include Influenza, Human.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00803595	Phase 3	Completed	Nov 1, 2008	Jun 1, 2009	Influenza, Human

Competing Products

20 competing products in Influenza, Human

See all competitors

Product	Company	Stage	Hype Score
Influenza vaccine, split inactivated	Comac Medical	Phase 1	25
Vaccine	Comac Medical	Phase 3	69
CT-P27 90 mg/kg + CT-P27 45 mg/kg + Placebo	Celltrion	Phase 2	52
CT-P27 + Placebo	Celltrion	Phase 2	52
CAIV-T	Pfizer	Phase 3	76
Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to Oseltamivir	Shionogi	Phase 3	77
Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to Oseltamivir	Shionogi	Phase 3	77
fH1 2 ug + fH1 8 ug + DSP-0546LP 2.5 ug + DSP-0546LP 5 ug + DSP-0546LP 10 ug + Placebo	Sumitomo Pharma	Phase 1	33
Monovalent Influenza Vaccine	AstraZeneca	Approved	85
Monovalent Influenza Vaccine	AstraZeneca	Approved	85
Trivalent Influenza Vaccine	AstraZeneca	Approved	85
AZD4117 + AZD5315	AstraZeneca	Phase 1/2	41
Trivalent Influenza Vaccine	AstraZeneca	Approved	85
FluMist trivalent (2015-2016) + FluMist Quadrivalent (2015-2016) + FluMist Quadrivalent (2017-2018)	AstraZeneca	Approved	85
Trivalent Influenza Virus Vaccine	AstraZeneca	Approved	85
Comparator: Modified Process Vaccine + Comparator: COMVAX™	Merck	Phase 3	77
Molnupiravir + Placebo molnupiravir + Placebo oseltamivir + Oseltamivir + Influenza A Virus	Merck	Phase 1	33
V512 + Comparator: Placebo to V512	Merck	Phase 1	33
Vaxelis + PedvaxHIB	Merck	Approved	85
Seasonal Influenza Vaccine	Novartis	Phase 2	52

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved

OAC aloneApproved

olmesartan medoxomil + Placebo + losartan potassiumApproved

Prasugrel + ClopidogrelApproved

Diet+pravastatinApproved